患者主导胰岛素滴定用于妊娠期糖尿病血糖管理:一项随机对照试验
EMPOWER 为单中心非盲随机对照试验,纳入 20–32 周需胰岛素的妊娠期糖尿病患者 56 例(干预组 29 例、对照组 27 例)。患者主导滴定(每晚起始 10 单位,根据空腹血糖每日增减 2 单位)与医生主导滴定相比,分娩前平均空腹血糖相似,但更快达到空腹血糖低于 95 mg/dL,且巨大儿和大于胎龄儿风险更低。
要点
- 患者主导滴定组分娩前平均空腹血糖 88.8 mg/dL,医生主导组 90.3 mg/dL,差异无统计学意义。
- 患者主导组达到空腹血糖低于 95 mg/dL 更快(平均 1.8 周 vs 2.5 周,HR 1.48,95%CI 1.16–1.90)。
- 患者主导组巨大儿风险 6.9% vs 37.0%(RR 0.18,95%CI 0.04–0.84),大于胎龄儿风险 3.3% vs 34.6%(RR 0.10,95%CI 0.08–0.12)。
核心结论
- 患者主导胰岛素滴定与医生主导滴定相比,分娩前平均空腹血糖相似,但血糖达标更快,巨大儿和大于胎龄儿风险更低。
研究设计与样本
- EMPOWER 为单中心、非盲随机对照试验,纳入 20–32 周需胰岛素的妊娠期糖尿病患者,2023 年 10 月 19 日至 2025 年 1 月 10 日进行,共 56 例随机(干预组 29 例、对照组 27 例),按意向性分析。
主要发现
- 患者主导组分娩前平均空腹血糖 88.8 mg/dL,医生主导组 90.3 mg/dL(β 系数 -1.50 mg/dL,95%CI -5.50 至 2.50)。
- 患者主导组达到空腹血糖低于 95 mg/dL 的平均时间 1.8 周,医生主导组 2.5 周(HR 1.48,95%CI 1.16–1.90)。
- 患者主导组巨大儿发生率 6.9%,医生主导组 37.0%(RR 0.18,95%CI 0.04–0.84)。
- 患者主导组大于胎龄儿发生率 3.3%,医生主导组 34.6%(RR 0.10,95%CI 0.08–0.12)。
- 其他妊娠结局和患者报告结局两组间无差异。
关键数值与推荐
- 干预组每晚起始长效胰岛素 10 单位,空腹血糖高于 95 mg/dL 每日增加 2 单位,低于 70 mg/dL 每日减少 2 单位。
- 对照组由临床医生决定起始剂量并每周滴定。
- 主要结局为孕 36 周或早产分娩前一周的平均空腹血糖。
临床怎么用
- 对于需胰岛素的妊娠期糖尿病患者,可考虑采用患者主导的每日胰岛素滴定方案以加快血糖达标并可能降低巨大儿和大于胎龄儿风险。
局限性
- 单中心、非盲设计,样本量较小(56 例),需更大规模以患者为中心的试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To conduct a randomized controlled trial (RCT) to assess whether patient-led insulin titration (intervention) compared with clinician-led insulin titration (control) resulted in improved glycemic management and pregnancy outcomes for individuals with gestational diabetes mellitus (GDM). METHODS: EMPOWER (Patient Versus Provider-Led Titration of Insulin for Glycemic Control in Gestational Diabetes) was a single-center, nonblinded RCT among individuals with GDM requiring insulin between 20 and 32 weeks of gestation that was conducted from October 19, 2023, to January 10, 2025. Intervention participants self-titrated long-acting insulin, which was started at 10 units nightly and decreased or increased by 2 units per fasting glucose above or below 70 and 95 mg/dL, respectively, every day. Control participants started an insulin dose with weekly titration at the clinician's discretion. The primary outcome was mean fasting glucose in the 36th week or the week before delivery for preterm deliveries. Secondary outcomes included pregnancy outcomes and patient-reported measures. With 80% power, two-sided α of 0.05, and 5% loss-to-follow-up, 56 individuals needed to be randomized to demonstrate at least a 15% difference in mean fasting glucose. Analysis was by intention to treat. RESULTS: Of 89 individuals who were eligible during the study period, 56 consented and were randomized (29 intervention, 27 control). The median duration from starting insulin to delivery was 7.7 weeks. Patient-led insulin titration resulted in a similar mean fasting glucose before delivery compared with clinician-led titration (88.8 vs 90.3 mg/dL; β coefficient -1.50 mg/dL, 95% CI, -5.50 to 2.50) but resulted in more rapid achievement of fasting glucose below 95 mg/dL (mean 1.8 weeks vs 2.5 weeks; hazard ratio 1.48, 95% CI, 1.16 to 1.90). Patient-led titration was associated with a lower risk of macrosomia (6.9% vs 37.0%, relative risk 0.18, 95% CI, 0.04 to 0.84) and large-for-gestational-age (LGA) birth weight (3.3% vs 34.6%, relative risk 0.10, 95% CI, 0.08 to 0.12). Other pregnancy and patient-reported outcomes did not differ between the groups. CONCLUSION: Patient-led insulin titration for GDM resulted in a similar mean fasting glucose compared with clinician-led insulin titration but was associated with more rapid achievement of glycemic control and a lower risk of macrosomia and LGA birth weight. These data support the need for larger patient-centered GDM treatment trials. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT05922033.
引用
- Wang XY, Grobman WA, Wu J, et al. Patient-Led Insulin Titration for Glycemic Management With Gestational Diabetes Mellitus: A Randomized Controlled Trial. Obstet Gynecol. 2026. PMID: 41712937. doi:10.1097/AOG.0000000000006154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。